Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation
Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation
复制标题
DOI：
10.1016/j.amjcard.2004.02.071
复制
发表时间：
2004-06-15
影响因子：
2.8
通讯作者：
Katz, A
中科院分区：
文献类型：
--
作者：
Amit, G;Rosen, A;Katz, A
对114例心房颤动患者的临床结果进行了比较，这些患者接受了创新的普罗帕酮治疗，然后由于成本控制而用普通的普罗帕酮代替了这种药物。研究发现，在房颤复发、急诊室和住院率以及伴随治疗的必要性方面，仿制药配方至少与创新药物一样安全有效。(C) 2004年由摘录医学公司。
The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy. (C) 2004 by Excerpta Medica, Inc.